Healthcare / Drug Manufacturers - Specialty & GenericShenzhen
$3.26
+0.04 (+1.19%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-181.1M · quality 46.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
21/100
D
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.8B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-7.5%
↓Gross Margin
56.2%
↑Debt/Equity
0.03
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-11.4%
FCF CAGR
—
FCF margin
-58.3%
FCF / Net income
0.67x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $396.8M · net income $-345.4M · FCF $-231.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $396.8M | $396.8M | $466.5M | $498.1M | $570.9M |
| Net Income | $-345.4M | $-345.4M | $-20.4M | $83.3M | $-47.0M |
| EBITDA | $-326.6M | $-326.6M | $40.6M | $165.9M | $-25.7M |
| EPS | -0.16 | -0.16 | -0.01 | 0.04 | -0.02 |
| Gross Margin | 56.2% | 56.2% | 64.1% | 58.7% | 55.5% |
| Operating Margin | -43.7% | -43.7% | -15.4% | -6.1% | -8.3% |
| Net Margin | -87.0% | -87.0% | -4.4% | 16.7% | -8.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.03 | 0.03 | 0.00 | 0.00 | 0.00 |
| Current Ratio | 16.69 | 16.69 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-231.3M | $-231.3M | $-181.1M | $-31.9M | $94.2M |
| Returns | |||||
| ROE | -7.5% | -7.5% | -0.4% | 1.6% | -0.9% |
| Valuation | |||||
| P/E | — | — | — | 83.51 | — |
| EV/EBITDA | — | — | 95.24 | 25.13 | — |
| P/B | 1.49 | 1.49 | 1.24 | 1.33 | 1.52 |
| Growth & Yield | |||||
| Revenue Growth | -14.9% | -14.9% | -6.3% | -12.7% | — |
| EPS Growth | -1618.9% | -1618.9% | -124.9% | 280.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+6.6%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.01 → -0.16
Residual
+6.6%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.